cell-death

Documents about cell-death

• Apoptosis: A Review of Programmed Cell Death#6788OpenAlex
• Unraveling the Intriguing Interplay: Exploring the Role of Lncrnas in Caspase-Independent Cell Death#681777İzmir Yüksek Teknoloji Enstitüsü
• Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death#6739OpenAlex
• Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)#864360ClinicalTrials.gov
• A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).#1362528ClinicalTrials.gov
• Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)#846086ClinicalTrials.gov
• MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy#896290ClinicalTrials.gov
• Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)#864543ClinicalTrials.gov
• Nitric oxide induces p53-mediated cell death in human nasal epithelial cells#385398OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Programmed cell death-1: from a T-cell immune checkpoint to a regulator of Natural Killer cell biology#677814IRIS
• Development and prognostic evaluation of an integrative programmed cell death index in pancreatic cancer based on multiple cell death modalities.#154325NCBI PubMed Central
• A Deep‐Red‐Absorbing Osmium(II) Complex as a Photosensitizer for Photodynamic Therapy Inducing Immunogenic Cell Death#175722HAL (France)
• PRRSV subverts host programmed cell death network for immune evasion#4485Europe PMC
• Mechanisms and time course of cell death in pulsed field ablation#1251395HAL (France)
• Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)#1183710ClinicalTrials.gov
• Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)#994230ClinicalTrials.gov
• Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)#1151827ClinicalTrials.gov
• Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis#391871HAL (France)
• Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)#991933ClinicalTrials.gov
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)#910133ClinicalTrials.gov
• Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies#1443173ClinicalTrials.gov
• Cytotoxicity unleashed: how Prymnesium parvum extract drives RTgill-W1 rainbow trout cells into cell death.#136131PubMed
• REVIEW OF SIGNALING PATHWAYS AND MORPHOLOGICAL CHANGES OF PROGRAMMED CELL DEATH – APOPTOSIS#237736Zenodo (CERN)
• Mitotic defects and cell death in sodium valproate-treated HeLa cells#313098Repositório de Dados de Pesquisa da Unicamp Dataverse OAI Archive
• Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer#1454506ClinicalTrials.gov
• Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)#899129ClinicalTrials.gov
• First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)#1229044ClinicalTrials.gov
• KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)#827772ClinicalTrials.gov
• Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma#834701ClinicalTrials.gov
• KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)#1008511ClinicalTrials.gov
• A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)#826923ClinicalTrials.gov
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)#841484ClinicalTrials.gov
• Physiology in Cell Death Induction: Roles of Anion Channels and Disordered Cell Volume Regulation#70229J-STAGE (Japan)
• Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)#1322190ClinicalTrials.gov
• Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)#1410671ClinicalTrials.gov
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)#1438597ClinicalTrials.gov
• Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)#851463ClinicalTrials.gov
• Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)#1197089ClinicalTrials.gov
• A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)#1310702ClinicalTrials.gov
• A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)#1339512ClinicalTrials.gov
• Raw Data#318805Figshare
• Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)#870636ClinicalTrials.gov
• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)#917769ClinicalTrials.gov
• Regulation of Programmed Cell Death During C. Elegans Development#216392EliScholar
• eIF2α phosphorylation is pathognomonic for immunogenic cell death#1146116HAL (France)
• Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension#1349433ClinicalTrials.gov
• Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)#1396027ClinicalTrials.gov
• Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)#1409082ClinicalTrials.gov
• Receptor-interacting Protein Shuttles between Cell Death and Survival Signaling Pathways#1358199eScholarship
• A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study#914489ClinicalTrials.gov